Nu Skin (NUS)
Sells beauty, wellness, and ageLOC device products through social direct selling.
Something off on this page? Send us feedback.
Sells beauty, wellness, and ageLOC device lines through person-to-person and digital channels, with Rhyz adding manufacturing and investment operations. Revenue is mostly international and depends on sales-leader productivity, direct-selling rules, and ongoing Mainland China regulation.
Beauty and wellness lines include Nu Skin skin care, Pharmanex nutrition, Nutricentials, Beauty Focus, and ageLOC devices and supplements. Products are sold through direct selling, person-to-person marketing, and digital or social platforms rather than mass retail.
Operations are spread across the Americas, Asia, Europe, Africa, and Rhyz manufacturing businesses, with most revenue generated outside the United States. Rhyz adds owned manufacturing and investment capabilities that support supply-chain control, speed to market, and product development.
The model depends on active Sales Leaders, product launches that keep the channel engaged, and compliance with direct-selling rules. Mainland China remains a distinct regulatory dependency because its market uses licensed structures, sales employees, and independent marketers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $189.6M · Total debt $263.7M · Total assets $1.12B · Shareholders' equity $542.7M
- Revenue
- $320.1M
- Operating income
- −$59.3M
- Net income
- −$249.8M
HistoryDividendAnnual yield
| Institutions | 77.36% | 37.65M shares | |
|---|---|---|---|
| 169 holders · as of Jun 30, 2026 | |||
| Insiders | 6.52% | 3.18M shares | |
| 13 holders · as of Sep 10, 2026 | |||
| Strategic holders | 8.55% | 4.16M shares | |
| 1 holder · as of Feb 4, 2022 | |||
| Other | 7.57% | 3.68M shares | |
| remainder | |||
48.68M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.87% | 4.32M | as of Jun 30, 2026 |
Wellington Management Group LLPStrategic | 8.55% | 4.16M | filed Feb 4, 2022 |
American Century Companies IncInstitution | 4.73% | 2.30M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.21% | 2.05M | as of Jun 30, 2026 |
Acadian Asset Management LLCInstitution | 4.01% | 1.95M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | Laura Nathanson | director | −2,676 | $6.73 |
| Nov 11, 2025 | Steven Keith Hatchett | officer: Chief Product Officer | +5,500 | $9.61 |
- Herbalife
Direct-selling nutrition rival with global distributor overlap
- USANA Health Sciences
Direct-selling wellness peer in supplements and skincare
- Estée Lauder Companies
Prestige beauty leader contesting skincare and anti-aging spend
- Coty
Prestige and mass beauty peer across fragrance, color and skincare
- e.l.f. Beauty
Fast-growing masstige beauty rival in cosmetics and skincare
- LifeVantage
Direct-selling supplements and personal-care peer
- Medifast
Coach-guided weight-management peer in nutrition and wellness
- Oddity Tech
Digital-first beauty and wellness challenger
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nu Skin | $4.72 | −2.98% | $236.0M | — | 4.9 | 0.2 | −17.1% |
| Herbalife | $11.96 | −2.21% | $1.27B | 7.9 | 4.5 | 0.2 | +5.4% |
| USANA Health Sciences | $14.22 | −3.79% | $272.9M | — | 13.9 | 0.3 | −5.3% |
| Estée Lauder Companies | $98.06 | −2.22% | $36.27B | 200.6 | 29.6 | 2.4 | +6.5% |
| Coty | $2.64 | −1.12% | $2.35B | — | 8.3 | 0.4 | +1.3% |
| e.l.f. Beauty | $100.95 | −1.15% | $6.02B | 102.1 | 32.6 | 3.4 | +35.5% |
| LifeVantage | $6.06 | −2.57% | $78.5M | 15.5 | 20.9 | 0.4 | −23.1% |
| Medifast | $12.07 | −0.08% | $134.3M | — | — | 0.4 | −27.6% |
| Oddity Tech | $17.75 | −5.51% | $1.07B | 79.5 | 17.7 | 1.6 | −25.1% |
| Median | 79.5 | 17.7 | 0.4 | −2.0% |